Physician profile
Patrick Pierce
NPI 1821715889
$572.84
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $12.66 · 2023: $145 · 2024: $416.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $560.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $560.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $130.00 | 2023-2024 | |
| Exact Sciences Corporation | $103.48 | 2023-2024 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $91.98 | 2023-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $61.49 | 2023-2024 | Mounjaro |
| Novo Nordisk INC | $31.91 | 2024 | Rybelsus, Ozempic |
| Amgen INC. | $27.57 | 2024 | Repatha, Otezla |
| Kowa Pharmaceuticals America, INC. | $26.43 | 2022-2023 | Seglentis |
| Phadia US INC. | $20.32 | 2024 | Immunocap |
| Astrazeneca Pharmaceuticals Lp | $18.49 | 2024 | Breztri |
| Alkermes, INC. | $16.61 | 2024 | Vivitrol |
| Cranial Technologies, INC | $15.95 | 2024 | Doc Band |
| Dexcom, INC. | $14.96 | 2024 | Dexcom G6 Transmitter |
| Becton, Dickinson and Company | $13.65 | 2024 | Venclose Maven Catheter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Pierce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.